3 results
Approved WMOCompleted
During the course of the study 2 randomisation questions will be adressed. Both questions concern patients in the high risk group.Randomisation question 1: Will the addition of Doxorubicin to the first 4 standard IVA chemotherapy courses lead to a…
Approved WMOCompleted
To determine the safety, tolerability and pharmacokinetics of an 18-hour i.v. infusion of CLR325 in stable heart failure patients.
Approved WMOPending
To determine the safety and tolerability and to establish a preliminary RP2D and/or an MTD or an MAD of MK-4464 administered via IV infusion as monotherapy and in combination with pembrolizumab IV infusion